Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology reported a strong quarter to 31 December 2025, with cash and equivalents of $20.94 million and more than 63% of expenditure directed to R&D and drug manufacturing, supported by $8.8 million in new funding from early option conversions and a premium-priced private placement. Operationally, the company secured composition-of-matter patent filings over the (E,E)-bisantrene isoform, unveiled a new primary mechanism of action showing the drug binds and stabilises G-quadruplex DNA and RNA structures linked to key cancer drivers such as MYC, expanded its clinical strategy with new RC220 programs in EGFR-mutant non-small cell lung cancer and acute myeloid leukaemia, obtained ethics approval for the HARNESS-1 Phase 1a/b lung cancer trial, and strengthened its scientific leadership with the appointment of G4-drug specialist Professor Laurence Hurley, positioning Racura to advance multiple pivotal and combination studies through 2027.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian clinical-stage oncology company focused on developing novel small-molecule cancer therapies, notably its bisantrene-based candidates RC220 and (E,E)-bisantrene. The company targets major solid and blood cancer markets, including non-small cell lung cancer and acute myeloid leukaemia, and is also exploring cardioprotective combinations with existing chemotherapies.
Average Trading Volume: 220,213
Technical Sentiment Signal: Buy
Current Market Cap: A$482.4M
See more data about RAC stock on TipRanks’ Stock Analysis page.